Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

akero therapeutics inc - AKRO

AKRO

Close Chg Chg %
54.55 0.10 0.18%

Closed Market

54.65

+0.10 (0.18%)

Volume: 15.31M

Last Updated:

Dec 8, 2025, 4:00 PM EDT

Trade Now

Company Overview: akero therapeutics inc - AKRO

AKRO Key Data

Open

$54.52

 Day Range

54.42 - 54.83

52 Week Range

21.34 - 58.40

 Market Cap

N/A

Shares Outstanding

NaN

 Public Float

N/A

Beta

-0.40

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.75

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.91M

  

AKRO Performance

No Data Available

AKRO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Akero Therapeutics Inc - AKRO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
244.00K 260.00K 29.00K 18.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
244.00K 260.00K 29.00K 18.00K
Depreciation
244.00K 260.00K 29.00K 18.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+14.55% +6.56% -88.85% -37.93%
Gross Income
(244.00K) (260.00K) (29.00K) (18.00K)
Gross Income Growth
-14.55% -6.56% +88.85% +37.93%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
100.64M 114.90M 172.84M 285.40M
Research & Development
81.76M 85.28M 141.80M 247.50M
Other SG&A
18.88M 29.61M 31.04M 37.91M
SGA Growth
+25.90% +14.16% +50.43% +65.13%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(100.89M) (115.16M) (172.87M) (285.42M)
Non Operating Income/Expense
109.00K 3.86M 24.21M 38.03M
Non-Operating Interest Income
109.00K 3.86M 24.21M 38.03M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 739.00K 3.10M 4.67M
Interest Expense Growth
- - +319.35% +50.63%
-
Gross Interest Expense
- 739.00K 3.10M 4.67M
Interest Capitalized
- - - -
-
Pretax Income
(100.78M) (112.03M) (151.76M) (252.06M)
Pretax Income Growth
-27.23% -11.17% -35.46% -66.09%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
30.63K 41.84M 68.37M 64.69M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(30.63K) (41.84M) (68.37M) (64.69M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(100.78M) (112.03M) (151.76M) (252.06M)
Minority Interest Expense
- - - -
-
Net Income
(100.78M) (112.03M) (151.76M) (252.06M)
Net Income Growth
-27.23% -11.17% -35.46% -66.09%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(100.78M) (112.03M) (151.76M) (252.06M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(100.78M) (112.03M) (151.76M) (252.06M)
EPS (Basic)
-2.8936 -2.8738 -2.8869 -3.7544
EPS (Basic) Growth
-14.94% +0.68% -0.46% -30.05%
Basic Shares Outstanding
34.83M 38.98M 52.57M 67.14M
EPS (Diluted)
-2.8936 -2.8738 -2.8869 -3.7544
EPS (Diluted) Growth
-14.94% +0.68% -0.46% -30.05%
Diluted Shares Outstanding
34.83M 38.98M 52.57M 67.14M
EBITDA
(100.64M) (114.90M) (172.84M) (285.40M)
EBITDA Growth
-25.90% -14.16% -50.43% -65.13%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation HOLD Average Target Price 54.00
Number of Ratings 1 Current Quarters Estimate -0.94
FY Report Date 12 / 2025 Current Year's Estimate -3.61
Last Quarter’s Earnings -0.90 Median PE on CY Estimate N/A
Year Ago Earnings -3.75 Next Fiscal Year Estimate -4.01
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.94 -0.96 -3.61 -4.01
High Estimates -0.94 -0.96 -3.61 -4.01
Low Estimate -0.94 -0.96 -3.61 -4.01
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 12
OVERWEIGHT 0 0 0
HOLD 1 7 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Buy

Insider Actions for Akero Therapeutics Inc - AKRO

Date Name Shares Transaction Value
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Mark T. Iwicki Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Andrew Cheng President and CEO; Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Andrew Cheng President and CEO; Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Dec 10, 2025 Seth L. Harrison Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00

Akero Therapeutics Inc in the News